Investor Panel: Navigating Partnerships, & Investment Challenges in Psychosis Drug Development
Time: 3:00 pm
day: Day Two
Details:
- Explore the scientific, regulatory, and commercial uncertainties that make psychosis R&D a uniquely high-risk category, and how these risks shape both pharma and investor interest
- Discuss how innovative startups and emerging biotech companies can forge mutually beneficial relationships with pharma and venture investors
- What makes a small biotech compelling? Insights into what large pharma and venture funds evaluate when considering assets or partnerships in psychosis, including key milestones, data quality, and leadership
- Practical advice for startups on how to initiate, navigate, and sustain productive conversations with investors and BD teams. What are red flags vs. green lights in early outreach?
- How government funding bodies, NIH consortia, and public research initiatives can complement private capital and de-risk early-stage psychosis innovation
